Enhancing antitumoral drugs with our "smart antitumoral nanovectors"

Ohmline is a synthetic glycolipid patented by Lifesome Therapeutics (CAS number 2757462-45-4). Ohmline monomers self-assemble into nanoparticles (liposomes) and elongated nanotubes (useful in therapeutic depots) when formulated in aqueous solutions. With minor modifications to the synthesis protocol, Ohmline can accommodate drugs of different size and solubility at either the core of its nanostructures (hydrophilic drugs) or at their surface (hydrophobic ones).

However, what truly makes Ohmline stand out among other lipid nanoparticles in the market is its intrinsic antitumoral activity. Contrary to already commercialized lipid nanoparticles, empty Ohmline structures (without cargo) can limit tumor growth in a wide array of different cancer cell lines in vitro, representing tumors as varied as prostate, lung, melanoma, colon and glioblastoma (see Supporting Figure 1). Data on hematologic tumors is also available upon request.

Thanks to this unique feature, Ohmline nanoparticles can establish synergies with the antitumoral drugs encapsulated on them, thus significantly enhancing their efficacy. We have extensively validated this ability with the clinically relevant chemotherapeutic docetaxel, obtaining great synergy interactions for the different types of cancer explored (Supporting Figure 2). Data with other standard-of-care drugs are also available upon request.

Do you have a promising antitumoral drug that you would like to see moving from the bench to successful clinical trials? Talk to us and we would be delighted to help you! We are always looking for perfect synergies!